CLDI — Calidi Biotherapeutics, Inc.

Is CLDI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Calidi Biotherapeutics, Inc. (CLDI) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.08. The rating moved from Neutral to Oversold on October 3, 2026.

See all oversold Healthcare stocks →

AI analysis

Calidi Biotherapeutics, Inc. (CLDI) is an early-stage biotherapeutics company with limited public financial disclosures and no clear near-term revenue drivers in the provided data. The stock is highly sensitive to clinical-readout outcomes, equity financing needs, and microcap liquidity dynamics; market risk-off sentiment and a cooling healthcare IPO/early‑stage funding environment increase short-term downside pressure. Key upside would require positive translational/clinical data, partnerships or non-dilutive capital; key downsides include trial setbacks, dilution and adverse policy/pricing developments affecting specialty therapeutics. Given current information gaps, outlook scenarios remain binary and confidence in forward projections is limited.

Key factors

  • Very early-stage clinical/preclinical biotherapeutics focus with limited commercial revenue visibility
  • Thin liquidity and microcap market dynamics that amplify volatility and sensitivity to market risk-off flows
  • Potential near-term catalysts tied to clinical readouts or partnership announcements (binary upside events)
  • Lack of recent EDGAR/reporting detail included in the provided data (transparency and runway uncertainty)
  • Sector backdrop: risk-off sentiment and cooling healthcare IPO window reduce appetite for speculative biotech
  • Positive longer-term thematic support for successful late-stage biologics and rare-disease therapies, which could lift sentiment if CLDI advances meaningful data

Risks

  • Clinical or preclinical program failure or inconclusive data leading to sudden share price declines
  • Equity dilution risk from near-term capital raises to fund operations and trials
  • Reimbursement and pricing pressure from Medicare negotiation and broader payer resistance for high-cost therapies
  • Intense competition from larger biopharma and platform players with deeper pockets and established commercialization channels
  • Regulatory delays or additional data requirements that extend timelines and increase cash burn
  • Very low trading volume / limited sell-side coverage increasing execution risk for investors

See today's live rating, score and targets

Members see the live hourly rating for CLDI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.